Sector
PharmaceuticalsOpen
₹136.8Prev. Close
₹135.5Turnover(Lac.)
₹1.62Day's High
₹138.8Day's Low
₹134.5552 Week's High
₹224.552 Week's Low
₹129.1Book Value
₹133.37Face Value
₹10Mkt Cap (₹ Cr.)
138.84P/E
11.19EPS
12.1Divi. Yield
2.21Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 116.49 | 106.51 | 93.97 | 85.72 |
Net Worth | 126.74 | 116.76 | 104.22 | 95.97 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 78.24 | 73.7 | 51.59 | 42.6 |
yoy growth (%) | 6.15 | 42.84 | 21.08 | -21.2 |
Raw materials | -26.86 | -28.73 | -22.84 | -19.41 |
As % of sales | 34.33 | 38.98 | 44.26 | 45.55 |
Employee costs | -8.83 | -7.37 | -7.46 | -6.47 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 27.72 | 23.32 | 8.86 | 5.92 |
Depreciation | -1.72 | -1.73 | -1.84 | -1.87 |
Tax paid | -6.75 | -5.76 | -3 | -2.84 |
Working capital | 18.28 | 25.77 | 12.46 | -5.5 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.15 | 42.84 | 21.08 | -21.2 |
Op profit growth | 15.53 | 136.91 | 50.59 | 105.44 |
EBIT growth | 18.87 | 162.9 | 47.6 | 111.6 |
Net profit growth | 13.8 | 199.5 | 90.41 | 24.84 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
G Ganesh Kumar
Independent Director
P Vijaya Lakshmi
Independent Director
Panchakarla Sai Sudhakar
Executive Director
G Sandeep Kumar
Independent Director
Venkataraju Gupta Kollepalli
Non Executive Director
Srinivas Gelli
Company Sec. & Compli. Officer
Pradosh Ranjan Jena.
H No C-21/A Road No 9,
Film Nagar Jubilee Hills,
Telangana - 500096
Tel: 91-40-23541688/23540933
Website: http://www.tycheindustries.net
Email: cs@tycheindustries.net; cfo@tycheindustries.com
214 RaghavaRatna Tow,
Chiragali Lane, Abids,
Hyderabad 500001
Tel: 91-040-23202465/2320
Website: www.cilsecurities.com
Email: cilsec@hotmail.com
Summary
Tyche Industries Limited (formerly known as Siris Soft Limited) was incorporated on Jul 23, 1998. TIL is one of the largest manufacturers in India of Glucosamine Hydrochloride and corresponding sodium...
Read More
Reports by Tyche Industries Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.